tbuckley/cabot-search huggingface dataset:
An Attempt to Identify Likely Precursors of Gastric Cancer&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: David State, M. D., Richard L. Varco, M. D., Owen H. Wangensteen, M. D.
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article An Attempt to Identify Likely Precursors of Gastric Cancer Get access David State, M. D., David State, M. D. Department of Surgery, University of Minnesota Medical School, Minneapolis Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard L. Varco, M. D., Richard L. Varco, M. D. Department of Surgery, University of Minnesota Medical School, Minneapolis Search for other works by this author on: Oxford Academic PubMed Google Scholar Owen H. Wangensteen, M. D. Owen H. Wangensteen, M. D. Department of Surgery, University of Minnesota Medical School, Minneapolis Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 5, April 1947, Pages 379–384, https://doi.org/10.1093/jnci/7.5.379 Published: 01 April 1947
Absent in melanoma 2 protein in systemic lupus erythematosus: friend or foe? Comment on the article by Lu et al
Authors: Wang‐Dong Xu, An‐Fang Huang
Journal: Arthritis & Rheumatology (2022)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Surgeon
Authors: Richard M. Stillman
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Photoreceptor Layer Thinning Is an Early Biomarker for Age-Related Macular Degeneration
Authors: Seyedeh Maryam Zekavat, Sayuri Sekimitsu, Yixuan Ye, Vineet Raghu, Hongyu Zhao, Tobias Elze, Ayellet V. Segrè, Janey L. Wiggs, Pradeep Natarajan, Lucian Del Priore, Nazlee Zebardast, Jay C. Wang
Journal: Ophthalmology (2022)
Abdominal trauma
Authors: D. L. Gilday, J. M. Ash
Journal: Clinical Nuclear Medicine (1991)

The triage of patients with blunt abdominal trauma is as follows. Life-threatening conditions must be corrected first. Often severe skeletal injuries have to be immobilized to prevent further damage. In the course of the patient's management, plain radiographs may be taken that can help evaluate the abdomen. If head or spinal injuries are present they must be evaluated and treated before the abdomen. If computed tomography (CT) or magnetic resonance imaging (MRI) is being carried out for this purpose, the sections of the abdomen can be used to screen the major organs for injury. If CT or MRI is not being performed, then usually radionuclide kidney and liver and spleen single-photon emission computed tomography (SPECT) imaging can be used to evaluate these organs. Ultrasound may be substituted but in some cases is not as reliable (Froelich, 1982).
Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis
Authors: Jacob S. Keith, Matthew M. McDonough, Jordan D. Dimitrakoff
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Extracellular Vesicles as Novel Players in Kidney Disease
Authors: Charles J. Blijdorp, Dylan Burger, Alicia Llorente, Elena S. Martens-Uzunova, Uta Erdbrügger
Journal: Journal of the American Society of Nephrology (2022)

"Urine can provide us day by day, month by month, and year by year with a serial story of the major events within the kidney." Dr. Thomas Addis, pioneer in renal physiology, came to this conclusion in 1948. The discovery of urinary extracellular vesicles (uEVs) as molecular mimics of kidney
THE SMALL DEATH RATE FROM DISEASE IN THE JAPANESE ARMY.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
International Comments
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neonatology
Authors: L. J. I. Zimmermann, M. de Jong, J. de Ouden, M. C. M. van Oosten, A. T. Kragten, P. J. J. Sauer, J. E. H. Bunt, V. P. Carnielli, R. H. T. van Beek, I. H. T. Luijendijk, J. den Ouden, P. C. Clemens, S. J. Neumann, F. B. Plötz, R. A. van Lingen, A. P. Bos, B. H. Doray, J. Orquin, J. N. van den Anker, S. S. Stephensen, R. M. Kleppesto, J. M. Tréluyer, V. Bastard, A. Sertin, C. Settegrana, P. Bourget, P. Hubert, H. L. Halliday
Journal: Intensive Care Medicine (1996)
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Authors: Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen, Gong-cheng Wang, Zhe-Sheng Chen, Cong-hui Han
Journal: Molecular Cancer (2022)

The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance. The genes that associated with cisplatin resistance remain unclear. Herein, we aimed to identify the cisplatin resistance associated genes in BUC. EXPERIMENTAL DESIGN: The cytotoxicity of cisplatin was evaluated in six bladder cancer cell lines to compare their responses to cisplatin. The T24 cancer cells exhibited the lowest sensitivity to cisplatin and was therefore selected to explore the mechanisms of drug resistance. We performed genome-wide CRISPR screening in T24 cancer cells in vitro, and identified that the gene heterogeneous nuclear ribonucleoprotein U (HNRNPU) was the top candidate gene related to cisplatin resistance. Epigenetic and transcriptional profiles of HNRNPU-depleted cells after cisplatin treatment were analyzed to investigate the relationship between HNRNPU and cisplatin resistance. In vivo experiments were also performed to demonstrate the function of HNRNPU depletion in cisplatin sensitivity.Significant correlation was found between HNRNPU expression level and sensitivity to cisplatin in bladder cancer cell lines. In the high HNRNPU expressing T24 cancer cells, knockout of HNRNPU inhibited cell proliferation, invasion, and migration. In addition, loss of HNRNPU promoted apoptosis and S-phase arrest in the T24 cells treated with cisplatin. Data from The Cancer Genome Atlas (TCGA) demonstrated that HNRNPU expression was significantly higher in tumor tissues than in normal tissues. High HNRNPU level was negatively correlated with patient survival. Transcriptomic profiling analysis showed that knockout of HNRNPU enhanced cisplatin sensitivity by regulating DNA damage repair genes. Furthermore, it was found that HNRNPU regulates chemosensitivity by affecting the expression of neurofibromin 1 (NF1).Our study demonstrated that HNRNPU expression is associated with cisplatin sensitivity in bladder urothelial carcinoma cells. Inhibition of HNRNPU could be a potential therapy for cisplatin-resistant bladder cancer.
Decreasing Liver Biopsy Complications
Authors: Florian Froehlich
Journal: Annals of Internal Medicine (1993)

Letters1 September 1993Decreasing Liver Biopsy ComplicationsFlorian Froehlich, MD, Michael Fried, MD, and Jean-Jacques Gonvers, MDFlorian Froehlich, MDSearch for more papers by this author, Michael Fried, MDSearch for more papers by this author, and Jean-Jacques Gonvers, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-5-199309010-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the retrospective review by Janes and Lindor [1] on the outcome of patients hospitalized for complications after outpatient liver biopsy. The authors report a complication rate of 3.2%. The varying reported complication rates of liver biopsy may be explained in part by the use of different needle types [2]. Complications have been more frequent with the Tru-Cut (Baxter, Valencia, California) needle than with the Menghini needle [3]. The high complication rate in Janes and Lindor's review, compared with other studies [2, 3], could therefore be caused by the predominant use (92%) of Tru-Cut ...References1. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993; 118:96-8. Google Scholar2. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: How safe is it? Ann Intern Med. 1993; 118:150-3. Google Scholar3. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicenter retrospective study on 68 276 biopsies. J Hepatol. 1986; 2:165-73. Google Scholar4. Chuah SY, Moody GA, Mayberry JF. The practice, complications and mortality of liver biopsy: a survey amongst members of the British Society of Gastroenterology. Gut. 1992; 33(Suppl):16. Google Scholar5. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsyresults of a nationwide survey in Switzerland. Dig Dis Sci. 1993 (In press). Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byComplications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience 1 September 1993Volume 119, Issue 5Page: 436-437KeywordsBiopsyGastroenterology and hepatologyLiverOutpatients ePublished: 15 August 2000 Issue Published: 1 September 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Multiple Myeloma
Authors: Study Committee of the Midwest Cooperative Chemotherapy Group
Journal: JAMA (1964)

MUCH IS KNOWN about the manifestations and natural course of myeloma, but there are features that have not been adequately elaborated. Information on progressive changes in various measurements during the course of illness would have particular value, as one might use serial observation of these measures more effectively in evaluating potential therapeutic agents. The establishment of objective criteria has permitted a more precise evaluation of new drugs in the treatment of acuteleukemia. The present study was initiated to provide information which would be similarly helpful in the evaluation of therapy in multiple myeloma. This report is concerned with diagnosis, indications for treatment, and most distressing manifestations of multiple myeloma, and particularly with patient survival. A subsequent publication will explore more fully the potential utility of various other measures as yardsticks of therapy in multiple myeloma.
Intra-articular injections in capsulitis.
Journal: BMJ (1991)

instructions, Fenem, New York), but, given the circumstances in which it would most rewardingly be used-cardiac arrests, resuscitation on the ward or in the emergency room, and resuscitation outside hospital by paramedical staff-this is not enough.The device has been shown to be ineffective when wet2; when very cold; when contaminated with lignocaine, atropine, adrenaline, or bicarbonate
Effect of Sleep Extension on Objectively Assessed Energy Intake Among Adults With Overweight in Real-life Settings
Authors: Esra Tasali, Kristen Wroblewski, Eva Kahn, Jennifer Kilkus, Dale A. Schoeller
Journal: JAMA Internal Medicine (2022)

Short sleep duration has been recognized as a risk factor for obesity. Whether extending sleep duration may mitigate this risk remains unknown.To determine the effects of a sleep extension intervention on objectively assessed energy intake, energy expenditure, and body weight in real-life settings among adults with overweight who habitually curtailed their sleep duration.This single-center, randomized clinical trial was conducted from November 1, 2014, to October 30, 2020. Participants were adults aged 21 to 40 years with a body mass index (calculated as weight in kilograms divided by height in meters squared) between 25.0 and 29.9 and had habitual sleep duration of less than 6.5 hours per night. Data were analyzed according to the intention-to-treat principle.After a 2-week habitual sleep period at baseline, participants were randomized to either an individualized sleep hygiene counseling session that was intended to extend their bedtime to 8.5 hours (sleep extension group) or to continue their habitual sleep (control group). All participants were instructed to continue daily routine activities at home without any prescribed diet or physical activity.The primary outcome was change in energy intake from baseline, which was objectively assessed as the sum of total energy expenditure and change in body energy stores. Total energy expenditure was measured by the doubly labeled water method. Change in body energy stores was computed using regression of daily home weights and body composition changes from dual-energy x-ray absorptiometry. Sleep duration was monitored by actigraphy. Changes from baseline were compared between the 2 groups using intention-to-treat analysis.Data from 80 randomized participants (mean [SD] age, 29.8 [5.1] years; 41 men [51.3%]) were analyzed. Sleep duration was increased by approximately 1.2 hours per night (95% CI, 1.0 to 1.4 hours; P < .001) in the sleep extension group vs the control group. The sleep extension group had a significant decrease in energy intake compared with the control group (-270 kcal/d; 95% CI, -393 to -147 kcal/d; P < .001). The change in sleep duration was inversely correlated with the change in energy intake (r = -0.41; 95% CI, -0.59 to -0.20; P < .001). No significant treatment effect in total energy expenditure was found, resulting in weight reduction in the sleep extension group vs the control group.This trial found that sleep extension reduced energy intake and resulted in a negative energy balance in real-life settings among adults with overweight who habitually curtailed their sleep duration. Improving and maintaining healthy sleep duration over longer periods could be part of obesity prevention and weight loss programs.ClinicalTrials.gov Identifier: NCT02253368.
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function
Authors: Eliana Ruggiero, Erica Carnevale, Aaron Prodeus, Zulma Irene Magnani, Barbara Camisa, Ivan Merelli, Claudia Politano, Lorena Stasi, Alessia Potenza, Beatrice Claudia Cianciotti, Francesco Manfredi, Mattia Di Bono, Luca Vago, Michela Tassara, Sara Mastaglio, Maurilio Ponzoni, Francesca Sanvito, Dai Liu, Ishina Balwani, Rossella Galli, Marco Genua, Renato Ostuni, Matteo Doglio, Daniel O’Connell, Ivy Dutta, Stephanie Ann Yazinski, Mark McKee, Mohamed Simo Arredouani, Birgit Schultes, Fabio Ciceri, Chiara Bonini
Journal: Science Translational Medicine (2022)

T cell receptor (TCR)–based therapy has the potential to induce durable clinical responses in patients with cancer by targeting intracellular tumor antigens with high sensitivity and by promoting T cell survival. However, the need for TCRs specific for shared oncogenic antigens and the need for manufacturing protocols able to redirect T cell specificity while preserving T cell fitness remain limiting factors. By longitudinal monitoring of T cell functionality and dynamics in 15 healthy donors, we isolated 19 TCRs specific for Wilms’ tumor antigen 1 (WT1), which is overexpressed by several tumor types. TCRs recognized several peptides restricted by common human leukocyte antigen (HLA) alleles and displayed a wide range of functional avidities. We selected five high-avidity HLA-A*02:01–restricted TCRs, three that were specific to the less explored immunodominant WT1 37–45 and two that were specific to the noncanonical WT1 −78–64 epitopes, both naturally processed by primary acute myeloid leukemia (AML) blasts. With CRISPR-Cas9 genome editing tools, we combined TCR-targeted integration into the TCR α constant ( TRAC ) locus with TCR β constant ( TRBC ) knockout, thus avoiding TCRαβ mispairing and maximizing TCR expression and function. The engineered lymphocytes were enriched in memory stem T cells. A unique WT1 37–45 -specific TCR showed antigen-specific responses and efficiently killed AML blasts, acute lymphoblastic leukemia blasts, and glioblastoma cells in vitro and in vivo in the absence of off-tumor toxicity. T cells engineered to express this receptor are being advanced into clinical development for AML immunotherapy and represent a candidate therapy for other WT1-expressing tumors.
Genomic DNA extraction from small amounts of serum to be used for α<sub>1</sub>‐antitrypsin genotype analysis”. S. Andolfatto, F. Namour, A‐L. Garnier, F. Chabot, J‐L. Gueant, I. Aimone­Gastin.<i>Eur Respir J</i>2003; 21: 215–219.
Journal: European Respiratory Journal (2003)
Fundamental Problems,
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types
Authors: Tae Yoon Park, Mark D.M. Leiserson, Gunnar W. Klau, Benjamin J. Raphael
Journal: Cell Genomics (2022)

Recent genome-wide CRISPR-Cas9 loss-of-function screens have identified genetic dependencies across many cancer cell lines. Associations between these dependencies and genomic alterations in the same cell lines reveal phenomena such as oncogene addiction and synthetic lethality. However, comprehensive identification of such associations is complicated by complex interactions between genes across genetically heterogeneous cancer types. We introduce and apply the algorithm SuperDendrix to CRISPR-Cas9 loss-of-function screens from 769 cancer cell lines, to identify differential dependencies across cell lines and to find associations between differential dependencies and combinations of genomic alterations and cell-type-specific markers. These associations respect the position and type of interactions within pathways: for example, we observe increased dependencies on downstream activators of pathways, such as NFE2L2, and decreased dependencies on upstream activators of pathways, such as CDK6. SuperDendrix also reveals dozens of dependencies on lineage-specific transcription factors, identifies cancer-type-specific correlations between dependencies, and enables annotation of individual mutated residues.